CHE.NYSEChemed CORP
10-K: Chemed Corporation Files 2023 Annual Report on Form 10-K
Sentiment:
Annual Results
Chemed Corporation has filed its annual report on Form 10-K for the fiscal year ended December 31, 2023, detailing its financial performance and business activities.
Summary
- Chemed Corporation's 2023 annual report on Form 10-K has been filed, covering the fiscal year ending December 31, 2023.
- The company operates through two main segments: VITAS, which provides hospice and palliative care, and Roto-Rooter, which offers plumbing and drain cleaning services.
- The report includes details on the company's financial performance, business operations, risk factors, and legal proceedings.
- Chemed's corporate office is responsible for strategic planning, capital allocation, and financial reporting.
- The company has engaged in twelve significant acquisitions or divestitures since its inception.
- Over 90% of VITAS revenue comes from the U.S. government through the Medicare program.
- Roto-Rooter's business is highly competitive with many local and regional firms.
- The company's research and development expenditures are not expected to be material.
- Both VITAS and Roto-Rooter are subject to extensive government regulations.
- VITAS is subject to periodic surveys and audits by regulatory authorities.
- The company has a Corporate Integrity Agreement with the Office of the Inspector General that concluded on June 22, 2023.
- Medicare payments for hospice services are subject to caps and limitations.
- The company is subject to various federal and state anti-kickback laws.
- Roto-Rooter's operations are subject to environmental laws and regulations.
- As of December 31, 2023, the company had 15,087 employees.
- Roto-Rooter acquired one franchise in South Carolina for $305,000 and one in Georgia for $3.689 million in 2023.
- VITAS purchased the hospice assets of one Florida provider for $1.24 million in 2022.
- The company's stock repurchase program has $314.1 million remaining as of December 31, 2023.
- The company's primary market risk exposure relates to interest rate risk through its variable interest credit facility.
Sentiment
Score: 7
Explanation: The document presents a balanced view of the company's performance, highlighting both positive aspects and potential risks. The company's financial results are generally in line with expectations, and the management commentary is positive. However, the document also acknowledges the challenges and risks associated with the company's operations, which prevents a higher sentiment score.
Positives
- The company has a diversified business model with two distinct operating segments.
- VITAS has a strong revenue base from the U.S. government through the Medicare program.
- Roto-Rooter has a well-recognized brand and a large customer base.
- The company has a stock repurchase program in place.
- The company has a strong focus on employee safety and training.
- The company has a robust cybersecurity program.
- The company has a strong focus on diversity and inclusion.
- The company has a strong focus on hiring and retaining talent.
Negatives
- VITAS is highly dependent on payments from Medicare and Medicaid.
- Roto-Rooter faces intense competition from numerous fragmented competitors.
- The company is subject to extensive government regulations.
- The company is subject to various legal proceedings.
- The company is subject to cybersecurity risks.
- The company is subject to reputational risks.
- The company is subject to natural disaster risks.
- The company is subject to interest rate risks.
Risks
- Intense competition in both the hospice and plumbing industries could impact market share and profitability.
- Changes in Medicare and Medicaid payment rates or methods could significantly affect VITAS revenue.
- Failure to comply with government regulations could result in fines, sanctions, or loss of licenses.
- The loss of key management personnel or the inability to hire and retain skilled employees could negatively impact operations.
- Cybersecurity breaches could compromise sensitive customer and patient information.
- Adverse publicity or negative online reviews could damage brand reputation.
- Natural disasters, particularly in Florida, could disrupt operations.
- Changes in interest rates could increase the cost of borrowing.
- The company is subject to certain anti-takeover statutes that might make it more difficult to effect a change in control of the Company.
- The company has historically incurred debt to finance the operations of the Company.
Future Outlook
The company estimates VITAS revenue to increase 9.0% to 9.8% in 2024, with an adjusted EBITDA margin of 17.8% to 18.3%. Roto-Rooter is forecasted to achieve full-year 2024 revenue growth of 3.5% to 4.0% with an adjusted EBITDA margin of 28.7% to 29.1%. Full-year 2024 earnings per diluted share, excluding certain items, is estimated to be in the range of $23.30 to $23.65.
Management Comments
- The company recognizes and appreciates that our employees are crucial to our success.
- The company believes that its vision of providing the best available patient and family care is delivered by its committed and compassionate employees.
Industry Context
The hospice care industry is highly competitive and fragmented, with many small, community-based providers. The plumbing and drain cleaning industry is also highly competitive, with many local and regional firms. The company competes on the basis of service quality, brand recognition, and pricing.
Comparison to Industry Standards
- Chemed's reliance on Medicare and Medicaid for VITAS revenue is typical of the hospice industry, where government programs are the primary payers.
- Roto-Rooter's fragmented competitive landscape is consistent with the plumbing and drain cleaning industry, where local and regional players dominate.
- The company's focus on employee safety and training aligns with industry best practices for service-oriented businesses.
- The company's cybersecurity measures are in line with the increasing focus on data protection in the healthcare and service industries.
- The company's stock repurchase program is a common practice among publicly traded companies to return value to shareholders.
- The company's financial performance is comparable to other companies in the healthcare and service sectors, with a focus on revenue growth and profitability.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | NA | Michael D. Witzeman | 2024-01 | Michael D. Witzeman was promoted to Chief Financial Officer in January of 2024. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Incentive Compensation Recovery Policy | The company adopted an Incentive Compensation Recovery Policy as of November 3, 2023, as required by Section 10D of the Securities Exchange Act of 1934, Rule 10D-1 under the Exchange Act and the applicable New York Stock Exchange Listing Standards. | 2023-11-03 | This policy is intended to apply independent of all other clawback, recoupment or forfeiture policies, agreements or other arrangements of the Company. |
Legal Proceedings
- The company is subject to various lawsuits and claims in the normal course of business.
- The company periodically receives communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at its VITAS subsidiary.
- VITAS is one of a group of hospice providers selected by the OIGs Office of Audit Services (OAS) for inclusion in an audit of the provision of elevated level-of-care hospice services.
- On October 30, 2017, the Company entered into a settlement agreement to resolve civil litigation under the False Claims Act brought by the United States Department of Justice (DOJ) on behalf of the OIG and various relators concerning VITAS.
- On October 16, 2020, VITAS received a Civil Investigative Demand (CID) issued by the U.S. Department of Justice (DOJ) pursuant to the False Claims Act concerning allegations of the submission of false claims for hospice services for which reimbursement was sought from federal healthcare programs, including Medicare.
- On November 30, 2022, VITAS received a Letter of Declination from the DOJ, informing VITAS that the United States was declining to intervene in this case giving rise to the CID, United States Ex. Rel. OKeefe v VITAS Healthcare Corporation , et al . that was unsealed on November 15, 2022.
- On April 6, 2023, the relator dismissed the case, without prejudice, with the consent of the United States.
- On August 29, 2022, six weeks subsequent to the OAS finalizing its audit, VITAS received a demand letter from its Medicare Administrative Contractor (MAC) seeking repayment of $ 50.3 million.
Stakeholder Impact
- Shareholders: The company's financial performance and stock repurchase program may impact shareholder value.
- Employees: The company's focus on employee safety, training, and compensation may impact employee morale and retention.
- Customers: The company's service quality and pricing may impact customer satisfaction.
- Patients: The company's hospice care services may impact patient comfort and well-being.
- Suppliers: The company's purchasing decisions may impact supplier relationships.
- Creditors: The company's debt levels and financial performance may impact creditor confidence.
Next Steps
- The company will continue to monitor the impact of the pandemic on its business.
- The company will continue to evaluate cash utilization alternatives, including share repurchase, debt repayment, acquisitions, and increased dividends.
- The company will continue to focus on employee safety and training.
- The company will continue to improve methods for detecting and preventing cyberattacks.
Key Dates
| Date | Description |
|---|---|
| 1935 | Roto-Rooter trademarks and service marks have been used and advertised since this year. |
| 1970 | Chemed Corporation was incorporated in Delaware as a subsidiary of W.R. Grace & Co. |
| 1971-04-30 | Chemed succeeded to the business of W.R. Grace & Co.'s Special Products Group. |
| 1982-03-10 | Chemed remained a subsidiary of W.R. Grace & Co. until this date. |
| 1991 | Sale of DuBois Chemicals Inc. (DuBois) resulting in potential environmental cleanup liabilities. |
| 1994-08-02 | Kevin J. McNamara first elected as President of the Company. |
| 1999-01-01 | Chemed/Roto-Rooter Savings & Retirement Plan effective date. |
| 2000-05-15 | Spencer S. Lee first elected as Executive Vice President of the Company. |
| 2001-06-01 | Excess Benefits Plan, as restated and amended, effective date. |
| 2006-05-15 | Certificate of Amendment to Certificate of Incorporation. |
| 2006-08-11 | 2006 Stock Incentive Plan, as amended. |
| 2006-12-01 | Employment Agreement with David P. Williams dated. |
| 2008-05-03 | Employment Agreement with Kevin J. McNamara dated. |
| 2009-07-09 | First Amendment to Employment Agreement with David P. Williams and Kevin J. McNamara dated. |
| 2010 | 2010 Stock Incentive Plan. |
| 2012-05-21 | Michael D. Witzeman first elected as Vice President, Chief Financial Officer, and Controller of the Company. |
| 2013-04-01 | Federal government implemented a 2% reimbursement cut for all Medicare programs, including hospice. |
| 2015 | 2015 Stock Incentive Plan. |
| 2016-06-16 | Nicholas M. Westfall first elected as Executive Vice President of the Company and Consulting Agreement with Timothy S. O'Toole dated. |
| 2017-10-30 | Settlement Agreement and Corporate Integrity Agreement effective date. |
| 2018 | 2018 Stock Incentive Plan. |
| 2018-08-03 | Chemed Corporation Change in Control Severance Plan and Senior Executive Severance Policy, as amended. |
| 2019-07-01 | Acquisition of a Roto-Rooter franchise and related assets in Oakland, CA. |
| 2019-08-02 | Asset Purchase Agreement to purchase substantially all of the assets of HSW RR, Inc. |
| 2019-10-01 | Rebasing of Medicare continuous care, inpatient care and respite care rates effective date. |
| 2020-05-01 | Suspension or reduction of the 2% Medicare reimbursement cut through a series of legislative measures. |
| 2020-08-31 | Brian C. Judkins first elected as Vice President and Chief Legal Officer of the Company. |
| 2020-10-16 | VITAS received a Civil Investigative Demand (CID) issued by the U.S. Department of Justice (DOJ). |
| 2022-01-01 | VITAS obtains the majority of its medical supplies from a single vendor. |
| 2022-05-16 | 2022 Stock Incentive Plan. |
| 2022-06-28 | Fifth Amended and Restated Credit Agreement by and among Chemed Corporation, JP Morgan Chase Bank NA, and other lenders. |
| 2022-07-01 | VITAS adopted the Difference Maker Program. |
| 2022-07-14 | VITAS received the final audit report from OAS. |
| 2022-08-29 | VITAS received a demand letter from its Medicare Administrative Contractor (MAC) seeking repayment of $50.3 million. |
| 2022-11-15 | United States Ex. Rel. OKeefe v VITAS Healthcare Corporation , et al. was unsealed. |
| 2022-11-30 | VITAS received a Letter of Declination from the DOJ. |
| 2022-12-09 | By-Laws of Chemed Corporation, as amended. |
| 2023-04-06 | The relator dismissed the case, without prejudice, with the consent of the United States. |
| 2023-06-22 | The OIG confirmed that VITAS satisfied its obligation under the CIA and that the CIA was concluded. |
| 2023-08-10 | The Centers for Medicare and Medicaid Services released the 2024 inflationary increase effective October 1, 2023, which was 3.1%. |
| 2023-10 | California enacted the Climate Corporate Data Accountability Act (SB 253) and Greenhouse Gases Climate-Related Financial Risk (SB 261). |
| 2023-11 | Board of Directors authorized an additional $300 million under the February 2011 Repurchase Program. |
| 2023-12-31 | End of fiscal year. |
| 2024-01 | Effective date of CMS Special Focus Program (SFP). |
| 2024-01-29 | David P. Williams Performance Share Units Grant Letter dated. |
| 2024-02-09 | 15,117,093 shares of Chemed Capital Stock (par value $1 per share) were outstanding. |
| 2024-02-29 | Date of the report. |
| 2024-05-20 | Annual Meeting to be held. |
Keywords
hospice, plumbing, Medicare, Medicaid, Roto-Rooter, VITAS, government regulations, cybersecurity, financial performance, acquisitions, stock repurchase, healthcare, drain cleaning, water restoration
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.